Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN Podcasts

*Podcasts play in a pop-up window. Please make sure your pop-up blocker is off.

GEN’s editor in chief, John Sterling, interviews life science academic and biotech industry leaders on important research, technology, and trends. These podcasts will keep you informed with all the important details you need.

John Sterling, GEN’s Editor in Chief, provides a preview of an upcoming session at next week’s BIO Conference and Exhibition in Chicago, which takes place from April 22-25. The session is entitled “Behind the Tech Transfer Headlines: What Are You Missing.” During the podcast, John interviews Jon Soderstrom, Ph.D., managing director of the office of cooperative research at Yale University and moderator of the BIO tech transfer session, and Atul Saran, senior vp of corporate development and ventures at MedImmune, one of the session panelists. Current and future trends in technology transfer are discussed.





  • Add a comment

  • Click here to Login/Register for free. You will be taken back to your selected item after Login/Registration.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »